A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
/in Dendritic Cells, International Publications, Ovarian CancerCurrent immunotherapeutic approaches in pancreatic cancer
/in Dendritic Cells, International Publications, Pancreatic CancerHER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy
/in Breast Cancer, Dendritic Cells, International PublicationsImmunotherapy for prostate cancer: biology and therapeutic approaches
/in Dendritic Cells, International Publications, Prostate CancerPulsing with blast cell lysate or blast-derived total RNA reverses the dendritic cell-mediated cytotoxic activity of cytokine-induced killer cells against allogeneic acute myelogenous leukemia cells
/in Acute Leukemia, Dendritic Cells, International PublicationsDendritic cells in cancer immunotherapy: vaccines or autologous transplants?
/in Dendritic Cells, International PublicationsAntigen-specific immunity and tumor inflammation after vaccination with BPX-101, a drug-activated dendritic cell vaccine for metastatic castration-resistant prostate cancer (mCRPC).
/in Dendritic Cells, International Publications, Prostate CancerChallenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1
/in Dendritic Cells, HIV/AIDS, International PublicationsIMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer